Crossmark

Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy

Crossref DOI link: https://doi.org/10.1038/s41598-025-18101-y

Published Online: 2025-10-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Singh, Apurva

Horng, Hannah

Roshkovan, Leonid

Hershman, Michelle

Cohen, Eric A.

Aggarwal, Charu

Carpenter, Erica L.

Katz, Sharyn I.

Kontos, Despina
Funding

Funding for this research was provided by:

National Institutes of Health (1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01, 1R01CA264835-01)
License Information

Text and Data Mining valid from 2025-10-03

Version of Record valid from 2025-10-03
More Information

Article History

Received: 3 April 2024

Accepted: 29 August 2025

First Online: 3 October 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below